Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rashmi K Murthy

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Breast Cancer Research and Treatment|April 15, 2023
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancerClinton Yam, Elizabeth A Mittendorf, Haven R Garber, et al.
JAMA Oncology|December 1, 2022
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical TrialNancy U Lin, Rashmi K Murthy, Vandana Abramson, et al.
Nature Cancer|March 19, 2026
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study resultsRashmi K Murthy, Barbara J O'Brien, Donald A Berry, et al.
Cancers|March 10, 2022
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast CancerNour Abuhadra, Ryan Sun, Jennifer K Litton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2020
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB TrialNancy U Lin, Virginia Borges, Carey Anders, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2022
Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast CancerClinton Yam, Nour Abuhadra, Ryan Sun, et al.
Cancers|July 14, 2023
Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective TrialNour Abuhadra, Ryan Sun, Clinton Yam, et al.
The New England Journal of Medicine|December 12, 2019
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast CancerRashmi K Murthy, Sherene Loi, Alicia Okines, et al.
Therapeutic Advances in Medical Oncology|August 7, 2023
PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimensHui Chen, Qingqing Ding, Laila Khazai, et al.
Cancer Research Communications|October 2, 2024
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II StudyClinton Yam, Miral Patel, Holly A Hill, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Breast Cancer Research and Treatment|April 15, 2023
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancerClinton Yam, Elizabeth A Mittendorf, Haven R Garber, et al.
JAMA Oncology|December 1, 2022
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical TrialNancy U Lin, Rashmi K Murthy, Vandana Abramson, et al.
Nature Cancer|March 19, 2026
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study resultsRashmi K Murthy, Barbara J O'Brien, Donald A Berry, et al.
Cancers|March 10, 2022
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast CancerNour Abuhadra, Ryan Sun, Jennifer K Litton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2020
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB TrialNancy U Lin, Virginia Borges, Carey Anders, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2022
Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast CancerClinton Yam, Nour Abuhadra, Ryan Sun, et al.
Cancers|July 14, 2023
Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective TrialNour Abuhadra, Ryan Sun, Clinton Yam, et al.
The New England Journal of Medicine|December 12, 2019
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast CancerRashmi K Murthy, Sherene Loi, Alicia Okines, et al.
Therapeutic Advances in Medical Oncology|August 7, 2023
PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimensHui Chen, Qingqing Ding, Laila Khazai, et al.
Cancer Research Communications|October 2, 2024
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II StudyClinton Yam, Miral Patel, Holly A Hill, et al.
Pageof 5